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Military medical facilities treating patients injured in Iraq and Afghanistan have identified a large number
of multidrug-resistant (MDR) Acinetobacter baumannii isolates. In order to anticipate the impact of these
pathogens on patient care, we analyzed the antibiotic resistance genes responsible for the MDR phenotype in
Acinetobacter sp. isolates collected from patients at the Walter Reed Army Medical Center (WRAMC). Sus-
ceptibility testing, PCR amplification of the genetic determinants of resistance, and clonality were determined.
Seventy-five unique patient isolates were included in this study: 53% were from bloodstream infections, 89%
were resistant to at least three classes of antibiotics, and 15% were resistant to all nine antibiotics tested.
Thirty-seven percent of the isolates were recovered from patients nosocomially infected or colonized at the
WRAMC. Sixteen unique resistance genes or gene families and four mobile genetic elements were detected. In
addition, this is the first report of blaOXA-58-like and blaPER-like genes in the U.S. MDR A. baumannii isolates
with at least eight identified resistance determinants were recovered from 49 of the 75 patients. Molecular
typing revealed multiple clones, with eight major clonal types being nosocomially acquired and with more than
60% of the isolates being related to three pan-European types. This report gives a “snapshot” of the complex
genetic background responsible for antimicrobial resistance in Acinetobacter spp. from the WRAMC. Identi-
fying genes associated with the MDR phenotype and defining patterns of transmission serve as a starting point
for devising strategies to limit the clinical impact of these serious infections.
The emergence and rapid spread of multidrug-resistant
(MDR) isolates of Acinetobacter spp. causing nosocomial in-
fections are of great concern worldwide (1, 23). The Centers
for Disease Control and Prevention recently highlighted the
enormity and gravity of MDR Acinetobacter baumannii infec-
tions in military medical facilities treating civilians and service
personnel injured in Iraq/Kuwait and Afghanistan (7). Antimi-
crobial susceptibility testing of these isolates originally re-
ported that more than half were resistant to three or more
classes of antibiotics. This resistance profile leaves clinicians
with limited therapeutic options. Another significant problem
is the large number of military personnel that may be colonized
by MDR Acinetobacter spp. (16). This reservoir would serve to
widely disseminate MDR Acinetobacter spp. As has been seen
with methicillin-resistant Staphylococcus aureus isolates and
vancomycin-resistant enterococci (VRE), patients who are col-
onized can spread MDR pathogens (5, 6, 30).
Here, we report an analysis of the antibiotic susceptibility
profile and genetic determinants of antibiotic resistance in 75
isolates of Acinetobacter spp. obtained from military and civil-
ian patients at the Walter Reed Army Medical Center
(WRAMC). This hospital was the major U.S. site receiving
casualties from the conflict in Iraq/Kuwait and Afghanistan.
Understanding the genetic background of antibiotic resistance
is an important step in defining the impact of MDR Acineto-
bacter spp. in military and civilian patients.
MATERIALS AND METHODS
Study population, bacterial isolate identification, and susceptibility testing.
The Acinetobacter sp. isolates were collected from 75 unique civilian and military
patients treated at the WRAMC in Washington, D.C. A medical record review
was performed for each case. For the purpose of this particular study, (i) clinical
infections were defined using standard criteria set by the National Nosocomial
Infections Surveillance System (40) and (ii) hospital-acquired infection was de-
fined as infection that occurred at least 72 h after arrival at the WRAMC. The
injury severity score (values from 0 to 75) was calculated based upon the method
of Baker et al. (3). Institutional Review Board approval for this retrospective
medical chart review was obtained at the WRAMC.
All isolates were collected from March 2003 through February 2005. Fifty-two
of the 75 isolates examined were collected from February 2004 to February 2005
and represent 67% of all isolates of Acinetobacter spp. collected at the WRAMC
during that time period. An additional 9% of Acinetobacter sp. isolates from that
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TABLE 1. Primers for amplification of genes from Acinetobacter sp. isolates
Primer name Primer sequence (5 to 3)a Annealingtemp (°C) Target gene(s)
Source or
reference
SHV PROX ATGCGTTATATTCGCCTGTG 60 All blaSHV genes 33
SHV DIS TGCTTTGTTATTCGGGCCAA
TEM 285 AAACGCTGGTGAAAGTA 45 All blaTEM genes 33
TEM 2023 AGCGATCTGTCTAT
CTX-M2-1 ATGATGACTCAGAGCATTCGCCGCT 70 blaCTX-M-2, blaCTX-M-4, blaCTX-M-5, 33
CTX-M2-2 TCAGAAACCGTGGGTTACGATTTTCG blaCTX-M-20, blaCTX-M-31, blaCTX-M-35,
blaTOHO-1
VEB-1 FOR ATGAAAATCGTAAAAAGGATATT 47 blaVEB-1, blaVEB-1A, blaVEB-1B, blaVEB-2, This study
VEB-1 REV TTATTTATTCAAATAGTAATTCC blaVEB-3
PER F-1 ATGAATGTCATTATAAAAG 44 blaPER-1 This study
PER R-2 TTGGGCTTAGGGCAG
IMP FOR GTTTATGTTCATACWTCG 45 blaIMP-1, blaIMP-2, blaIMP-4, blaIMP-5, This study
IMP REV GGTTTAAYAAAACAACCAC blaIMP-6, blaIMP-7, blaIMP-8, blaIMP-9,
blaIMP-10, blaIMP-11, blaIMP-15, blaIMP-19,
blaIMP-20, blaIMP-21
VIM FOR TTTGGTCGCATATCGCAACG 66 blaVIM-1, blaVIM-2, blaVIM-4, blaVIM-5, This study
VIM REV CCATTCAGCCAGATCGGCAT blaVIM-6, blaVIM-8, blaVIM-9, blaVIM-10,
blaVIM-11, blaVIM-12
GIM FOR ATATTACTTGTAGCGTTGCCAGC 61 blaGIM This study
GIM REV TTAATCAGCCGACGCTTCAG
ADC-7 FOR ATGCGATTTAAAAAAATTTCTTGT 50 blaADC-1, blaADC-2, blaADC-3, blaADC-4, 21
ADC-7 REV TTATTTCTTTATTGCATTCAG blaADC-5, blaADC-6, blaADC-7
OXA SET A FOR ATGAAAAAATTTATACTTCC 47 blaOXA-24, blaOXA-25, blaOXA-26, blaOXA-33, This study
OXA SET A REV TTAAATGATTCCAAGATTTTC blaOXA-40, blaOXA-72
OXA SET B FOR TCTGGTTGTACGGTTCAGC 51 blaOXA-23, blaOXA-27, blaOXA-49 This study
OXA SET B REV AGTCTTTCCAAAAATTTTG
OXA SET C FOR ACAGAARTATTTAAGTGGG 47 blaOXA-51, blaOXA-58, blaOXA-64, blaOXA-69, This study
OXA SET C REV GGTCTACAKCCMWTCCCCA blaOXA-70, blaOXA-71, blaOXA-75, blaOXA-78
OXA SET D FOR TAGCACTGCTTTTCTCAGCTG 51 blaOXA-20, blaOXA-37 This study
OXA SET D REV TTGACGGATTGAAGAATAGCACG
OXA1F ACACAATACATATCAACTTCGC 50 blaOXA-1, blaOXA-4, blaOXA-30, blaOXA-31, This study
OXA1R GTGTGTTTAGAATGGTGATC blaOXA-47
OXA58-5 ATGAAATTATTAAAAATATTGAGTTTAG 53 blaOXA-58, blaOXA-96 This study
OXA58-3 TTATAAATAATGAAAAACACCCAAC
Hep35 TGCGGGTYAARGATBTKGATTT 49 Conserved region intI1, intI2, intI3 53
Hep36 CARCACATGCGTRTARAT
Hep58 TCATGGCTTGTTATGACTGT 55 Class 1 integron cassette array 53
Hep59 GTAGGGCTTATTATGCACGC
ISABA1a ATGCAGCGCTTCTTTGCAGG 55 ISABA1 19
ISABA1b AATGATTGGTGACAATGAAG
IS1133 for AGTACAAAAGCTGTGAGATTTCAG 58 IS1133 This study
IS1133 rev GATATTCATGAGCGCAATATTGGCT
adeR-5 ATGTTTGATCATTCTTTTTCTTTTG 46 adeR (regulatory gene of AdeABC This study
adeR-3 TTAATTAACATTTGAAATATG efflux gene cluster)
adeE-5 ATGTTGTCGAGTTTTTTTATTGCACG 60 adeE (efflux gene of AdeDE) This study
adeE-3 TCATTTTGCCTTTTTGGTATTTAAC
aacA4 FOR ATGACTGAGCATGACCTTGCG 65 aacA4 This study
aacA4 REV TTAGGCATCACTGCGTGTTCG
aacC1-5 ATGGGCATCATTCGCACATGTAGG 64 aacC1 This study
aacC1-3 TTAGGTGGCGGTACTTGGGTC
aadA1-5 ATGAGGGAAGCGGTGATCG 62 aadA1 This study
aadA1-3 TTATTTGCCGACTACCTTGGTG
aadB-5 ATGGACACAACGCAGGTCGC 68 aadB This study
aadB-3 TTAGGCCGCATATCGCGACC
aphA6 FOR ATGGAATTGCCCAATATTATTC 55 aphA6 This study
aphA6 REV TCAATTCAATTCATCAAGTTTTA
aacC2 FOR ATGCATACGCGGAAGGCAATAAC 65 aacC2 This study
aacC2 REV CTAACCGGAAGGCTCGCAAG
gyrA-1 AAATCTGCCCGTGTCGTTGGT 63 gyrA (QRDRb) 52
gyrA-2 GCCATACCTACGGCGATACC
parC-1 AAACCTGTTCAGCGCCGCATT 58 parC (QRDR) 51
parC-2 AAAGTTGTCTTGCCATTCACT
QnrA GGGTATGGATATTATTGATAAAG 52 qnrA 27
QnrB CTAATCCGGCAGCACTATTA
CarO 5 ATGAAAGTATTACGTGTTTTAGTG 50 carO This study
CarO 3 TTACCAGTAGAAGTTTACACC
a Y  C or T; M  A or T; R  A or G; B  C, G, or T; W  A or T; K  G or T.
b QRDR, quinolone resistance-determining region.
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time period were received but eliminated from this study due to insufficient
patient information or being duplicate patient samples. In the case of duplicate
patient samples, the first collected Acinetobacter sp. isolate was chosen to elim-
inate bias.
Antimicrobial susceptibility testing was performed on the 75 isolates according
to the method established by the CLSI (formerly NCCLS) and interpreted with
criteria published in 2005 (9, 31). Isolates were tested using cation-adjusted
Mueller-Hinton agar (BBL MH II; Becton Dickinson Microbiology Systems,
Sparks, MD). Meropenem, imipenem, ampicillin, ampicillin-sulbactam, cipro-
floxacin, ceftazidime, cefepime, amikacin, and tobramycin disks (Becton Dick-
inson Microbiology Systems) were used.
Multidrug resistance was defined in this analysis as resistance to three or more
representatives of the following classes of antibiotics: quinolones (ciprofloxacin),
extended-spectrum cephalosporins (ceftazidime and cefepime), -lactam/-lac-
tamase inhibitor combination (ampicillin-sulbactam), aminoglycosides (amikacin
and tobramycin), and carbapenems (imipenem and meropenem).
PCR amplification, cloning, DNA sequencing, and restriction endonuclease
digestion. All target genes and corresponding primers used for PCR amplifica-
tion are listed in Table 1. Positive controls were used for -lactamase gene
amplification as follows: blaSHV-1 cloned into pBC SK() (Stratagene, La Jolla,
CA), blaTEM-1 cloned into the commercially available pBR322 (New England
BioLabs, Beverly, MA), blaADC-7 cloned into pBC SK(), blaCTX-M-2 cloned into
the pCR 2.1-TOPO vector (Invitrogen, Carlsbad, CA), RGN238 blaOXA-1 con-
struct, the isolate containing blaIMP-2 (a kind gift from G. Rossolini), and Pseudo-
monas aeruginosa PU21 possessing blaPER-1 (a kind gift from F. Danel) (11, 21,
38, 39, 45). Positive control reactions for blaVIM, blaGIM, and blaVEB-1 were not
performed. For OXA set A to D, positive controls were also not used. Presump-
tive positive PCR products for -lactamase genes were identified according to
size and either cloning into the pCR-XL-TOPO vector followed by sequencing or
direct sequencing of the PCR product. PCR product identification via pCR-XL-
TOPO vector cloning and sequencing was carried out for representative blaADC,
blaOXA-23-like, blaOXA-69-like, blaOXA-58-like, and blaPER positive amplicons.
Direct sequencing of select positive amplicons was carried out for blaSHV and
blaTEM. For all other PCR amplifications, the products obtained were considered
presumptive positives based on amplicon size. These include PCR amplification
reactions for all aminoglycoside-modifying enzyme (AME) genes, all quinolone
resistance-determining regions (QRDRs) of gyrA and parC genes, adeE, adeR,
carO, and int genes, variable regions of class 1 integrons, and insertion (IS)
elements. In the case of a negative PCR, in which a positive control was not used,
PCR amplifications were repeated at least twice for these genes. A negative
control was run with every PCR.
For PCR, a 1:10 dilution of an overnight culture was boiled for 10 min.
Amplification was then performed with 10 l of this dilution as the DNA
template. PCR conditions included 30 cycles of amplification under the following
conditions: denaturation at 95°C for 30 s, annealing for 1 min at primer set-
specific temperatures (Table 1), and extension at 72°C for 1 min/kb product.
Cycling was followed by a final extension at 72°C for 10 min. PCR products were
resolved on 1.0% agarose gels, stained with ethidium bromide, and photo-
graphed with UV illumination. Either the 1-kb DNA ladder or the 100-bp DNA
ladder (Promega, Madison, WI) was used to assess PCR product size.
Amplification and HinfI (Promega) digestion of the QRDRs of topoisomerase
IV parC and gyrA genes in Acinetobacter spp. were performed as follows. For the
restriction endonuclease digestion, 40 l of PCR amplification product was
purified using a QIAquick PCR purification kit (QIAGEN, Valencia, CA) ac-
cording to the manufacturer’s protocol. The eluant was incubated at 37°C for
2.5 h with 10 U of HinfI. The digests were then separated by electrophoresis in
1.5% NuSieve (FMC BioProducts, Rockland, ME) plus 1.0% agarose gel stained
with ethidium bromide and photographed with UV illumination. To serve as a
control, the remaining 10 l of undigested PCR product from each sample was
resolved on the same agarose gel.
PCR products generated and cloned into pCR-XL-TOPO were sequenced
using an ALF Express II automated DNA sequencer (Amersham Biosciences,
Piscataway, NJ) with a Thermo Sequenase fluorescence-labeled primer cycle
sequencing kit (Amersham Biosciences) and Cy5-labeled M13 reverse and M13
universal primers (21). pCR-XL-TOPO clones containing the bla genes were
cycle sequenced under the following conditions: DNA was heated to 94°C for 1
min, followed by 30 cycles of 94°C for 30 s, 55°C for 1 min, and 60°C for 2 min.
Direct sequencing was performed for blaTEM and blaSHV genes by using previ-
ously described Cy5-labeled TEM104 reverse, TEM164 forward, and A forward
primers under the same cycling conditions as those described above (20, 21).
Clonal determination by PCR ESI-MS. To determine clonal relatedness by
PCR electrospray ionization mass spectroscopy (PCR ESI-MS), the conserved
regions of six bacterial housekeeping genes (efp, trpE, adk, mutY, fumC, and ppa)
were amplified from each isolate by using eight sets of previously validated
primers (14). The amplification products were then desalted and purified, and
the mass spectra were determined using previously established protocols (13).
These base compositions were compared to those of 23 isolates representing
three major A. baumannii clone types (I, II, and III) that have spread throughout
Europe (50). In addition, 26 American Type Culture Collection (ATCC) Acineto-
bacter sp. reference strains were used for Acinetobacter species verification. The
European isolates and ATCC control strains used for this analysis were recently
described by Ecker et al. (14).
RESULTS
Characteristics of the study population. Acinetobacter sp.
isolates were recovered from 75 patients: 67 men (89%) and 8
(11%) women. Patients in this study included active duty sol-
diers or civilians (e.g., contractors injured in Iraq) sent to
Iraq/Kuwait or Afghanistan and civilians (family members of
active duty soldiers and retirees eligible for care) hospitalized
at the WRAMC. One patient was deployed to Afghanistan and
57 (76%) to Iraq/Kuwait, while 17 (23%) were nondeployed.
More than half (63%) of the patients had positive Acineto-
bacter sp. cultures less than 3 days from the time of admittance.
The relevant descriptive statistics of the study population are
summarized in Table 2. The mean age ( SD) of the popula-
tion was 35 ( 18) years, with a range of 5 to 86 years. When
Acinetobacter spp. were isolated, 53 patients (71%) were in an
intensive care unit (ICU) or step-down unit, 51 (68%) were
mechanically ventilated, and 66 patients (88%) had an indwell-
ing central venous catheter. Sixty-seven patients (89%) had
clinical infections and eight (11%) were colonized. Overall,
five deaths (7% mortality rate) were observed in patients with
A. baumannii infection (Table 3). Taken as a unique group,
these five patients were older and were immunosuppressed.
The death rate of the nondeployed patients was 29%. It is also
TABLE 2. Characteristics of the study populationa
Parameter
(units unless otherwise specified)
No. (%) of
patients
Mean  SD
(range minimum,
maximum	)
Duration of hospitalization (days) 75 53  48 (3, 205)
Duration of ICU stay (days) 75 19  35 (0, 205)
Time febrile (days) 75 11  11 (0, 51)
Total surgeries (no.) 75 6  6 (0, 23)
Different antibiotics used (no.) 75 6  4 (1, 17)
Duration of antibiotic use (days) 75 38  37 (1, 205)
Changes to antibiotic regimen (no.) 75 5  5 (0, 21)
Debridement procedures (no.) 75 4  5 (0, 22)
Injury severity score 58 21  12 (4, 59)
APACHE II scoreb 17 15  10 (0, 30)
Hospital locations
Surgical ICU 24 (32)
Medical ICU 26 (35)
ICU step-down 3 (4)
ONPc 11 (15)
Surgery 4 (5)
Internal medicine 4 (5)
Emergency room 3 (4)
a Patients in this study were civilians eligible for care (contractors injured in
Iraq, family members of active duty soldiers, or retirees) and active duty military
personnel hospitalized at the WRAMC.
b The APACHE (Acute Physiology and Chronic Health Evaluation) II Score
was calculated at the time of admission to ICU (medical and surgical).
c ONP, orthopedics/neurology/physical medicine and rehabilitation.
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notable that these isolates were from patients hospitalized for
a prolonged period of time (Table 3).
Antimicrobial susceptibility. Table 4 summarizes the sites of
isolation and antibiotic resistance patterns found in these iso-
lates compared to Meropenem Yearly Susceptibility Test In-
formation Collection (MYSTIC) data for Acinetobacter spp. in
the United States during 2004. Isolates obtained at the
WRAMC demonstrated significantly more resistance to cipro-
floxacin, ceftazidime, cefepime, amikacin, tobramycin, imi-
penem, and meropenem (ampicillin-sulbactam was not avail-
able for comparison) than the U.S. Acinetobacter spp. collected
in 2004.
Overall, 89% of the isolates were resistant to at least three
classes of antibiotics, hence meeting the criteria for multidrug
resistance. More than 90% of the isolates were resistant to
ciprofloxacin, and at least 80% were resistant to extended-
spectrum cephalosporins. Nearly half (49%) of the isolates
were also resistant to ampicillin-sulbactam. Notably, imipenem
resistance was observed in 20% of isolates and meropenem
resistance was detected in 25%. Eighty-one percent of isolates
were resistant to at least one aminoglycoside (amikacin or
tobramycin). Quite alarmingly, 11 isolates (15%) were resis-
tant to the five classes of antibiotics tested.
Genotypic analysis: -lactamase genes. Table 5 lists the
detected -lactamase genes and the genes encoding the AMEs.
Detailed genetic and phenotypic analyses of specific isolates
can be found in Table 6. The ampC Acinetobacter-derived
cephalosporinase, blaADC, was detected in 99% of the collec-
tion by PCR amplification (21). This cephalosporinase is re-
sponsible for resistance to ceftazidime and other extended-
spectrum cephalosporins. Three distinct blaOXA-like genes
were also identified. Using PCR, a blaOXA-69-like gene was
found in 97% of the isolates (17). In two carbapenem-suscep-
tible isolates (AB002 and AB006), ISABA1 was found to be
proximal to the blaOXA-69-like gene. The blaOXA-23-like car-
bapenemase gene was detected in 11% of strains (12, 18), and
the blaOXA-58-like carbapenemase gene was found in an addi-
tional 12% of the isolates (10, 35). Seventeen of 19 isolates
(90%) that were imipenem and/or meropenem resistant by disk
diffusion possessed evidence for the presence of a blaOXA-23-like
or a blaOXA-58-like gene (Table 6). All eight isolates that con-
tained a blaOXA-23-like gene were shown to have insertion
sequence ISABA1 proximal to the gene, as previously reported
by others (18, 49).
PCR amplification of class A -lactamase genes revealed
that 40% (30/75) of the isolates contained blaTEM, only one
isolate contained blaSHV, and two isolates contained blaPER
(24, 34). This is also the first description of blaPER in the
United States. Evidence for other common Acinetobacter
TABLE 3. Mortality associated with MDR A. baumannii infections in nonmilitary personnela
Isolate Age (yr) Underlying condition(s) Hospital dayof death Attributable mortality
AB001 71 Chronic obstructive pulmonary disease 27 Ventilator-associated pneumonia
AB002 35 Renal transplant 44 Pneumonia and lung abscess
AB029 85 Abdominal aortic aneurysm 88 Ventilator-associated pneumonia
AB052 72 Congestive heart failure, chronic renal failure 45 Pneumonia and sepsis
AB056 76 Dementia 93 Anoxic brain injury and bacteremia
a The sixth death was a 21-year-old active duty soldier admitted due to a severe trauma blast. This patient died on hospital day 17 due to a pulmonary embolus. He
previously had A. baumannii bacteremia (AB017) during his hospital course. All isolates except for AB029 were bloodstream infections and were acquired in the
hospital.
TABLE 4. Anatomical sites of isolation and antibiotic resistance
patterns of isolates in this study
Anatomical
site
No. of
isolates
% Resistance toa:
CIP CAZ FEP SAM AMK TOB IPM MEM
All 75 91 91 84 49 53 67 20 25
Bloodstream 40 90 90 88 58 50 70 23 25
Skin 18 89 94 78 56 61 72 17 28
Wound 8 100 100 75 25 50 75 13 13
Respiratory b 5 80 60 80 40 60 60 20 20
Urine 2 100 100 100 100 100 50 50 50
Intravenous
catheter
1 100 100 100 100 0 0 0 0
Cerebrospinal
fluid
1 100 100 100 100 0 0 0 0
MYSTIC c 44 42 32 NRd 14 13 8 8
a CIP, ciprofloxacin (quinolone); CAZ, ceftazidime (cephalosporin); FEP,
cefepime (cephalosporin); SAM, ampicillin-sulbactam (-lactam/-lactamase in-
hibitor); AMK, amikacin (aminoglycoside); TOB, tobramycin (aminoglycoside);
IPM, imipenem (carbapenem); MEM, meropenem (carbapenem).
b Includes bronchoalveolar lavage fluid, trachea, and sputum.
c Includes Acinetobacter spp. in the United States during 2004 in all specialties
(http://www.mystic-data.org).
d NR, not reported.
TABLE 5. Percentage of each antibiotic resistance gene detected in
the collection of Acinetobacter sp. isolates from the WRAMC
Gene % Detectionin isolates
Genes encoding -lactamases
blaADC...........................................................................................................99
blaOXA-69-likea .............................................................................................97
blaOXA-23-likeb .............................................................................................11
blaOXA-58-likec..............................................................................................12
blaTEM...........................................................................................................40
blaSHV ........................................................................................................... 1
blaPER............................................................................................................ 3
Genes encoding AMEsd
aacC1 ............................................................................................................56
aacC2 ............................................................................................................ 5
aadA1 ............................................................................................................39
aadB ..............................................................................................................48
aphA6 ............................................................................................................71
a Includes blaOXA-51-, blaOXA-58-, blaOXA-64-, blaOXA-69-, blaOXA-70-, blaOXA-71-,
blaOXA-75-, and blaOXA-78-like genes.
b Includes blaOXA-23-, blaOXA-27-, and blaOXA-49-like genes.
c Includes blaOXA-58- and blaOXA-96-like genes.
d aacC1 confers gentamicin resistance. aacC2 confers tobramycin and genta-
micin resistance. aadA1 confers streptomycin and spectinomycin resistance. aadB
confers tobramycin, gentamicin, and kanamycin resistance. aphA6 confers ami-
kacin, gentamicin, kanamycin, and neomycin resistance.
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-lactamase genes was absent (blaCTX-M and other blaOXA
genes), including the carbapenem-hydrolyzing metallo--lacta-
mase genes blaIMP, blaVIM, and blaGIM.
DNA topoisomerase mutations and quinolone resistance.
More than 90% of our isolates were resistant to ciprofloxacin.
HinfI digestion of the QRDR amplification products of gyrA
and parC in these isolates indicated that 88% contain a point
mutation at Ser83 in gyrA or Ser80 in parC leading to quino-
lone resistance. Except for two isolates, this analysis correlated
with susceptibility studies (Table 6). Our primers did not detect
the presence of the plasmid-mediated quinolone resistance
gene qnrA in these 75 isolates (27, 42).
Genes encoding AMEs. Screening for genes encoding AMEs
demonstrated that 97% of the isolates that are amikacin resis-
tant contained the phosphotransferase gene aphA6 (Tables 5
and 6). Other genes encoding AMEs included the adenylyl-
transferase genes aadA1 (39%) and aadB (48%) and the acetyl-
transferase genes aacC1 (56%) and aacC2 (5%). Seventy-eight
percent (40/51) of the tobramycin-resistant isolates contained
either the aacC2 or aadB gene.
Genes encoding efflux pumps. An important resistance de-
terminant in A. baumannii is the AdeABC efflux pump (26,
28). A. baumannii isolates demonstrating enhanced expression
of this pump are resistant to aminoglycosides, quinolones, tet-
racyclines, and trimethoprim. The AdeABC operon possesses
two genes that encode proteins that act as a sensor (adeS) and
a regulator (adeR) of the pump. This regulatory gene was
identified in 95% of the isolates. The expression of the AdeABC
efflux pump is being further evaluated.
We also detected the efflux pump gene adeE (part of the
AdeDE pump in Acinetobacter genome species 3) (8). This
amplicon was found in two isolates that did not contain the
AdeABC pump (Table 6). By PCR ESI-MS, these two isolates
were determined not to be A. baumannii (see below).
Mobile genetic elements. Integrons are genetic elements
harboring multiple antibiotic resistance genes. Central to the
genetic organization of the integron is the integrase gene (int).
The isolates were screened for intI1, intI2, and intI3 genes,
class 1 integron specific gene cassettes, and the insertion se-
quence elements (IS1133 and ISABA1). Sixty-one percent of the
isolates demonstrated evidence of int genes. Nearly 70% of
these contained class 1 integron gene cassettes of various sizes
(data not shown).
Ninety-five percent of the isolates contained ISABA1 and 5%
of the isolates contained IS1133, another IS element associated
with increased expression of the ADC -lactamase in A. bau-
mannii (19, 44). These two IS elements were found together in
four isolates. We did not uncover evidence that the IS elements
were located 5 to the blaADC genes, but we are continuing to
map the location of the IS elements. We also showed that in
certain isolates, ISABA1 is proximal to the blaOXA-69-like gene
and to the blaOXA-23-like resistance determinant as described
above.
Species identification and clonality by PCR ESI-MS. PCR
ESI-MS is a form of high-throughput multilocus sequence typ-
ing that is able to distinguish Acinetobacter isolates at the
species level as well as to determine clonality (13). Using this
technique, we identified at the genetic level 73 A. baumannii
isolates, 1 Acinetobacter genome species 3 isolate, and 1 Acineto-
bacter johnsonii isolate. There was a distribution of 16 different
clone types identified within the collection. Further analysis
revealed eight main clone types. All eight main types were
involved in nosocomial acquisition (28 patients, 37% of iso-
lates) (Table 6). It is notable that carbapenem-resistant iso-
lates were composed of four distinct clones while three of these
types possessed blaOXA-23-like genes; the fourth, ESI-MS type
24, contained the blaOXA-58-like gene.
Interestingly, the base composition analysis of 21 of 23 ref-
erence strains representing European clones I, II, and III
matched 32% of the isolates exactly for all six housekeeping
loci tested (efp, trpE, adk, mutY, fumC, and ppa). Related
clones of European type I (ESI-MS types 16 and 46) and II
(ESI-MS types 1, 10, and 11) are found in an additional 37% of
the isolates (Table 7). These isolates are identical in five of the
TABLE 7. Distribution of Acinetobacter sp. PCR ESI-MS clone types isolated at the WRAMCa
European
type PCR ESI-MS type
No. of
isolates Hospital location(s) Time course
I 15b 4 SICU, MICU, ICU step-down May 2003–August 2004
I 16 1 ONP July 2004
I 46 2 MICU, ONP April 2003–May 2003
II 1 1 MICU October 2003
II 10 9 SICU, ONP, surgery, ICU step-down, internal
medicine, ER
August 2003–February 2005
II 11 15 SICU, MICU, ONP May 2003–November 2004
II 12b 4 SICU, MICU, internal medicine August 2004–December 2004
III 14b 16 SICU, MICU, ONP, surgery, ICU step-down May 2003–December 2004
§ 3 6 SICU, MICU, ONP July 2003–February 2005
§ 9 1 MICU October 2004
§ 24 11 SICU, MICU, ONP June 2004–February 2005
§ 39 1 MICU September 2003
§ 47 1 SICU January 2004
§ 48 1 SICU April 2004
§ Acinetobacter genome sp. 3 1 ER August 2003
§ A. johnsonii 1 ER January 2004
a All isolates are A. baumannii except Acinetobacter genome sp. 3 and A. johnsonii. §, Isolates not related to European strains. SICU, surgical intensive care unit;
MICU, medical intensive care unit; ONP, orthopedics/neurology/physical medicine and rehabilitation; ER, emergency room.
b Exact matches to European reference strains.
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six genetic loci examined. Sequence variations occurred only
within the mutY locus, suggesting that these isolates are vari-
ants of the well-characterized European strains. Consistent
with previous studies comparing the relatedness and aminogly-
coside resistance of these pan-European strains, clone type III
(ESI-MS type 14) remains the most uniform in its antibiogram
and genetic profiles, while clones I and II have slightly diverse
susceptibility and genetic patterns within each group (32, 50).
DISCUSSION
The goal of our study was to link the resistance phenotypes
and the genetic determinants of resistance in A. baumannii,
giving a “snapshot” of the complex nature of this endemic
situation. From these data, it is clear that the potential impact
of A. baumannii infections on military and civilian personnel in
receiving hospitals is significant.
A unique characteristic of our study is that bloodstream
infections were the most common clinical source of Acineto-
bacter spp. This may reflect the nature and severity of injury
among these patients: more than two-thirds of the patients
were critically ill, had central venous catheters, and were on
mechanical ventilation when their isolates were obtained.
Hence, in light of our susceptibility testing, empirical mono-
therapy for bloodstream infections would be inappropriate.
Only two isolates in this collection are resistant to both ami-
kacin and imipenem-cilistatin, and therefore, combination
therapy with these antibiotics would ensure that at least one
agent is effective for the majority of isolates. It is notable these
isolates (from the WRAMC) have a broader range of resis-
tance than those (from the MYSTIC) typically found in U.S.
hospitals (Table 4).
A second striking feature of this study is the large number of
antibiotic resistance genes found in these isolates. Forty-nine
A. baumannii isolates had eight or more resistance determi-
nants. Our genetic analysis revealed that the blaADC and
blaOXA-69-like genes were present in nearly all of the strains
(17). More significantly, we have also detected for the first time
in the United States the presence of the blaOXA-58-like gene (4,
10, 12, 18, 29, 35, 37, 47, 49). OXA-23- and OXA-58-like
-lactamases contribute to meropenem and imipenem resis-
tance in 90% of the carbapenem-resistant isolates in this
collection. We also detected the presence of an IS element,
ISABA1, located proximal to the blaOXA-23-like genes in our
isolates. This IS element may act as a strong promoter and be
linked to higher levels of carbapenem resistance by increasing
-lactamase expression. This analysis is similar to contempo-
rary studies by Turton et al. (49), wherein IS elements (ISABA1
upstream of blaOXA-23-like genes) have been found in carbap-
enem-resistant A. baumannii isolates in the United Kingdom.
Insertion elements have also been shown to flank blaOXA-58
and enhance its expression (36). Interestingly, this is the first
description of blaPER in the United States.
It is possible that the carbapenem-resistant isolates also have
reduced permeability of the outer membrane, altered penicillin
binding proteins, or upregulated efflux pumps. We did not find
evidence for common metallo--lactamases (IMP, VIM, and
GIM type) that confer high levels of carbapenem resistance.
Investigations analyzing the outer membrane proteins in car-
bapenem-resistant isolates are in progress.
Many of our isolates were resistant to quinolones due to
mutations in the QRDR. Although two isolates do not have
these mutations, an upregulated efflux pump might account for
their quinolone resistance.
Aminoglycoside resistance (secondary to the presence of
genes encoding AMEs) was also prevalent. Many of these
genes are widespread in Pseudomonas aeruginosa and A. bau-
mannii and mirror those described in a collection of MDR A.
baumannii isolates from Europe (clone types I, II, and III) (22,
32). Unlike the European strains, we did not always find the
aminoglycoside gene aadA1 in conjunction with aacC1. As
previously shown, a significant proportion of the genes encod-
ing AMEs are contained in class 1 integrons. There was a 93%
correlation with the presence of aadA1 and int genes as pre-
viously described (2, 43, 48, 54).
Our analysis of the genetic relatedness of these 75 isolates by
PCR ESI-MS against 26 ATCC reference strains and 23 Eu-
ropean A. baumannii isolates firmly establishes the complexity
of the transmission dynamics of this endemic situation. It is
remarkable that more than 60% of the isolates were related to
the pan-European strains that have been collected from more
than 25 countries, including Spain, Greece, Portugal, Poland,
France, South Africa, The Netherlands, and Italy, over the last
20 years (32, 50). We further demonstrate that isolates from
each of the eight main clones (including all three pan-Euro-
pean types) were also responsible for the hospital-acquired
infections at the WRAMC. During the 13-month period, Jan-
uary 2004 to February 2005, seven of the eight main clone
types of A. baumannii simultaneously circulated at the
WRAMC (Table 7). Although we identified a total of 16
unique clone types, one limitation of our study is that the
isolates we analyzed may not have included all Acinetobacter
sp. clone types present at the WRAMC during the entire
collection period (March 2003 to February 2005).
Why are these MDR isolates spreading so readily? It has
been suggested that the epidemic potential of A. baumannii
may be linked to the presence of class 1 integrons that contain
antibiotic resistance genes (25). In an environment in which
antibiotics are frequently used, possessing integrons with mul-
tiple resistance determinants confers a strong selective advan-
tage (46). We found genetic evidence for the integron-encoded
integrase genes intI1, intI2, and intI3 in 60% of our collection
(Table 6). Class 1 integron cassettes were found in 43% of our
MDR isolates. As warned by Richet and Fournier, the major
concern regarding A. baumannii is the large repertoire of re-
sistance genes carried by a series of mobile genetic elements in
the genome (15, 41).
The majority of our population were previously healthy mil-
itary personnel that were wounded and became critically ill (58
patients sustained trauma and 53 patients were in an ICU).
Despite the large number of bloodstream isolates, mortality
rates were not high. Nevertheless, it is important to keep in
mind that mortality rates were higher in immunosuppressed
patients possessing MDR A. baumannii isolates (Table 3). Also
alarming is that MDR A. baumannii isolates with at least eight
resistance genes were frequently recovered from patients who
were intubated.
This study highlights the need for careful epidemiological
and molecular surveillance among receiving hospitals and re-
newed infection control policies with regard to Acinetobacter
VOL. 50, 2006 MDR A. BAUMANNII ISOLATES AT WRAMC 4121
 o
n
 O
ctober 22, 2015 by University of Queensland Library
http://aac.asm
.org/
D
ow
nloaded from
 
spp. It is significant that 37% of the isolates were nosocomial
in origin (obtained from patients colonized or infected at the
WRAMC). In light of these observations and the nature of the
multiclonal spread, we suspect that incomplete disinfection
procedures and environmental transmission are playing impor-
tant roles in the dissemination of Acinetobacter spp. in military
medical facilities. As with recounts of the genetic basis of
multidrug resistance in hospital outbreaks reported by Turton
et al., our paper describes isolates from patients that have been
transported from the combat theater hospitals in Iraq and
Afghanistan to the U.S. military medical facility in Landstuhl,
Germany (47). In Germany, they are stabilized prior to further
transport to the WRAMC for additional treatment (8,000
miles, three hospital settings). The various environments afford
multiple opportunities for acquisition and spread of Acineto-
bacter spp. The next challenge is to discern the impact of
resistance determinants on clinical outcomes.
Our comprehensive analysis is the first in depth study to link
the MDR phenotypes and clonality to the genetic determinants
of resistance to -lactams, aminoglycosides, and quinolones in
A. baumannii in the U.S. As we have learned with methicillin-
resistant S. aureus isolates and vancomycin-resistant entero-
cocci, many of these Acinetobacter sp. isolates may also serve as
reservoirs for antibiotic resistance genes that can be transmit-
ted to other pathogens. Hence, the potential introduction of
MDR Acinetobacter sp. isolates into European and American
civilian, military, and Veterans Affairs medical centers has far
reaching consequences. The implementation of specific educa-
tional programs, strategies for prevention of primary and sec-
ondary acquisition, and interventions designed to control this
emerging nosocomial pathogen needs to be an urgent imper-
ative in the care of civilian and military personnel in both
European and U.S. hospitals. The diversity and complexity of
the resistance determinants found and the potential for wide-
spread dissemination of these strains through Europe and
North America could lead to important changes in the global
epidemiology of A. baumannii-associated diseases.
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